StockpollyBeta
Get App
Popularity #1,487
PTCT · NASDAQ · Biotechnology

PTC Therapeutics (PTCT)

Develops rare-disease medicines spanning PKU, DMD, gene therapy, and RNA-splicing programs.

$65.96
After hours+0.01 (+0.02%)
At close$65.95(+1.06%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue1973072101871972131,176179211165273361
Cost of revenue9106151611161311116162820
Gross profit1872011951711861971,16316795148245341
30519824121124035919320292230199192
Research & development16412111613216112510911310013310199
8176737073858185841008681
Selling & marketing0−50000000000
General & administrative81810000000000
Other expenses6005110615034−92−41212
Operating income−1183−45−40−55−162970−353−8246149
−48−160−39−46−4368−40−36−26−57−48−51
Interest expense284441434241343033554948
Other non-operating income20116−222−10966−72−13
Income before tax−167−157−85−86−98−95930−71−23−139−298
Income tax expense−34−17139−2963−6−39−4014
Net income from continuing operations−133−156−92−99−107−66867−6516−135−383
Net income−133−156−92−99−107−66867−6516−135−383
EPS, basic−$1.76−$2.06−$1.20−$1.29−$1.39−$0.85$11.09−$0.83$0.20−$1.67−$0.03$1.01
EPS, diluted−$1.76−$2.06−$1.20−$1.29−$1.39−$0.85$10.04−$0.83$0.20−$1.67−$0.03$0.92
Weighted average shares, basic757676777777787881818383
Weighted average shares, diluted757676777777867887818392
EBITDA−74−3212−35−50−47971−3321−7162162
Depreciation & amortization6581557677811131516
EBIT−138−113−44−42−56−54964−4110−8447146